RemeGen Co., Ltd. (HKG:9995)

RemeGen Statistics

Total Valuation

RemeGen has a market cap or net worth of HKD 51.05 billion. The enterprise value is 52.15 billion.

Market Cap	51.05B
Enterprise Value	52.15B

Important Dates

The last earnings date was Thursday, October 30, 2025.

Earnings Date	Oct 30, 2025
Ex-Dividend Date	n/a

Share Statistics

RemeGen has 555.94 million shares outstanding. The number of shares has increased by 0.77% in one year.

Current Share Class	200.81M
Shares Outstanding	555.94M
Shares Change (YoY)	+0.77%
Shares Change (QoQ)	+4.08%
Owned by Insiders (%)	12.41%
Owned by Institutions (%)	59.26%
Float	463.67M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	20.97
PB Ratio	20.13
P/TBV Ratio	21.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-50.35
EV / Sales	21.42
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-147.87

Financial Position

The company has a current ratio of 0.96, with a Debt / Equity ratio of 0.94.

Current Ratio	0.96
Quick Ratio	0.66
Debt / Equity	0.94
Debt / EBITDA	n/a
Debt / FCF	-6.76
Interest Coverage	-12.31

Financial Efficiency

Return on equity (ROE) is -40.42% and return on invested capital (ROIC) is -12.08%.

Return on Equity (ROE)	-40.42%
Return on Assets (ROA)	-9.72%
Return on Invested Capital (ROIC)	-12.08%
Return on Capital Employed (ROCE)	-28.90%
Revenue Per Employee	811,874
Profits Per Employee	-345,342
Employee Count	2,999
Asset Turnover	0.38
Inventory Turnover	0.53

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +430.47% in the last 52 weeks. The beta is 0.86, so RemeGen's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	+430.47%
50-Day Moving Average	97.41
200-Day Moving Average	58.45
Relative Strength Index (RSI)	43.80
Average Volume (20 Days)	5,473,815

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RemeGen had revenue of HKD 2.43 billion and -1.04 billion in losses. Loss per share was -1.91.

Revenue	2.43B
Gross Profit	2.03B
Operating Income	-993.05M
Pretax Income	-1.04B
Net Income	-1.04B
EBITDA	-695.59M
EBIT	-993.05M
Loss Per Share	-1.91

Balance Sheet

The company has 1.29 billion in cash and 2.39 billion in debt, giving a net cash position of -1.10 billion or -1.97 per share.

Cash & Cash Equivalents	1.29B
Total Debt	2.39B
Net Cash	-1.10B
Net Cash Per Share	-1.97
Equity (Book Value)	2.54B
Book Value Per Share	4.59
Working Capital	-124.22M

Cash Flow

In the last 12 months, operating cash flow was -67.92 million and capital expenditures -284.75 million, giving a free cash flow of -352.67 million.

Operating Cash Flow	-67.92M
Capital Expenditures	-284.75M
Free Cash Flow	-352.67M
FCF Per Share	-0.63

Margins

Gross margin is 83.28%, with operating and profit margins of -40.79% and -42.54%.

Gross Margin	83.28%
Operating Margin	-40.79%
Pretax Margin	-42.54%
Profit Margin	-42.54%
EBITDA Margin	-28.57%
EBIT Margin	-40.79%
FCF Margin	n/a

Dividends & Yields

RemeGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.77%
Shareholder Yield	-0.77%
Earnings Yield	-2.03%
FCF Yield	-0.69%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RemeGen has an Altman Z-Score of 2.83 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.83
Piotroski F-Score	4